Naringenin and naringin in cardiovascular disease prevention: A preclinical review
Reza Heidari MoghaddamClinical Research Development Center, Imam Ali and Taleghani Hospital, Kermanshah University of Medical Sciences, Kermanshah, IranZeinab SamimiPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, 6734667149, IranSeyed Zachariah MoradiPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, 6734667149, Iran; Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, 6734667149, IranPeter J. LittleDepartment of Pharmacy, Xinhua College of Sun Yat-sen University, Tianhe District, Guangzhou, 510520, China; School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woollsiana, Queensland, 4102, AustraliaSuowen XuDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230037, China. Electronic address: [email protected]Mohammad Hosein FarzaeiPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, 6734667149, Iran; Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, 6734667149, Iran. Electronic address: [email protected]
2020en
ABI
Abstract
No abstract available.
Identifiers
Citations and references
Cited by 20 references